Terumo continues to deliver solid financial results, with steady revenue growth and margin improvement, but share price performance has lagged the broader med-tech sector. The company's strengths lie
Terumo Corporation (OTCPK:TRUMF) Q4 2025 Results Conference Call May 14, 2025 4:00 AM ET Company Participants Jin Hagimoto - Chief Financial Officer Hikaru Samejima - President & Chief Executive Offic
Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Balloon Catheters Patent Landscape Report" has been added to ResearchAndMarkets.com's offering.
Terumo Corporation (OTCPK:TRUMF) Q3 2025 Earnings Conference Call February 13, 2025 3:00 AM ET Company Participants Jin Hagimoto – Chief Financial Officer Conference Call Participants Jin Hagimoto [
Terumo Corporation (OTCPK:TRUMF) Q2 2025 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Jin Hagimoto – Chief Financial Officer Hikaru Samejima – Chief Executive Officer
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Terumo (TRUMY) a New Buy Stock

01:01pm, Thursday, 05'th Sep 2024
Terumo (TRUMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
Terumo Corporation (OTCPK:TRUMY) Q4 2024 Results Conference Call May 14, 2024 4:30 AM ET Company Participants Jin Hagimoto - CFO Hikaru Samejima - President, CEO & Director Jin Hagimoto I'm Hagimoto,
Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Momentum Stocks to Buy for March 28th

11:00am, Thursday, 28'th Mar 2024
TRUMY, CIFR and STR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 28, 2023.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE